Glucose sensing and continuous glucose monitoring (CGM) manufacturer for diabetes management, Dexcom, and pharmaceutical and medical devices organisation, Abbott, have been locked in a series of patent disputes over their continuous glucose monitoring (CGM) devices and systems, in a battle that spans multiple patents and several jurisdictions including the UK, US and Germany. In the UK alone, both parties have brough infringement proceedings, with a total of seventeen patents being at issue.
A recent decision issued by the Unified Patent Court (UPC) sees one of Dexcom’s patents revoked in its…
In January 2024 Cameroon launched the world’s first routine malaria vaccine programme. By incorporating the RTS,S vaccine into its standard immunisation schedule, Cameroon aims to protect thousands of children across Africa and significantly reduce malaria-related fatalities.
Closely following suit, the Côte d’Ivoire has recently become the first country to roll-out the new R21/Matrix-M™ vaccine, in another key advancement in the battle against malaria.
The launch of the vaccines, and the implementation of the mass vaccination programmes, marks a historic step in the global fight against…
Series C round led by Elevage Medical Technologies
Funding will accelerate the commercialization of Nuclera’s eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally
Cambridge, UK, and Boston MA, USA, 16 October 2024: Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has completed a USD $75 million financing round (circa £57 million). The fundraise was led by Elevage Medical Technologies, backed by Patient Square Capital, and joined…
Pioneer Group, the specialist life science infrastructure and venture-building company, welcomed 425 school children from 29 schools to eight of its sites across the UK this week to mark Ada Lovelace Day, an international celebration of the achievements of women in STEM.
The event was the seventh annual Ada Lovelace Day celebration run by Pioneer in collaboration with educational charity Ignite! and the biggest to date. The two-day event showcased the real-world impact of women in science through interactive workshops held at MediCity Nottingham, Kent Science Park, Wilton Centre, Hexagon…
Search HighlightsRecent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech. This quarter’s successful placements include:Function, Focus area, LocationCEO, Small molecule biopharma, AustraliaCEO, Medical devices, IsraelCEO, Nucleic acid therapies, UKCEO, Neurostimulation devices, BelgiumChief Medical Officer, Small molecule/ biologics platform, USChief Discovery Officer, Oncology platform technologies, AustriaPresident EMEA , Drug delivery systems, GermanyVP, Head of…
BioPORTER® protein delivery reagent from AMSBIO is proven to efficiently transport functionally active proteins directly into living cells eliminating the traditional DNA transfection, transcription, and protein translation process.
Employing a unique lipid-based protein delivery system – BioPORTER® makes studying protein functionality faster and easier than ever before. Comprising a proprietary cationic lipid mixture that interacts non-covalently with the protein, BioPORTER® creates a protective vehicle for immediate protein delivery directly into the cell cytoplasm.
BioPORTER® has…
Revolutionising Early-Stage Breast Cancer Treatment: How the MAF Test® Enhances Precision Care with Biomarker-Driven Insights
Read Article Here:
https://sourcebioscience.com/maf-test-revolutionising-early-stage-breas…
Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)
Cambridge, UK – 7 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40 patients at clinical centres in the UK, France, Italy and Spain. Initial data readouts are expected by the end of 2025.
Melanoma is a life-threatening skin cancer that can spread to…
Former AstraZeneca Senior Director, Global Project Leader adds significant experience and expertise to leadership team
Appointment will drive further development of Mosaic’s targeted oncology combination therapies pipeline and platform
Cambridge, UK, 07 October 2024 – Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, today announced the appointment of Dr Barry Davies as CSO, where he will lead the Company’s scientific strategy and Research and…
Dr Gordon McInroy appointed as COO, Dr Tobias Ost as SVP Product Development, and Charu Maini as SVP of People
Cambridge, UK, 02 October 2024: Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop eProtein Discovery™ system, today announced key leadership changes, including Dr Gordon McInroy’s promotion to the role of Chief Operating Officer, Dr Tobias Ost moves to become Senior Vice President Product Development and Charu Maini will take the role of Senior Vice President of People. Following a pivotal year for…